Dermata Phase 3 Acne Trial Update: Last Patent Completes Last Visit in Trial of Freshwater Sponge-based Treatment
The last patient has completed their last visit in Dermata Therapeutics, Inc.’s first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of Xyngari, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The Company remains on track to announce topline data by the end of March 2025. Xyngari is derived […]